US stock · Healthcare sector · Medical Devices

Edwards Lifesciences Corporation

NYSE

85.72

USD

+0.38

(+0.45%)

Market Open

34.82P/E

30Forward P/E

1.43P/E to S&P500

51.965BMarket CAP

- -Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

26 Jul-31 Jul

Shares Short

5/15/23

9.84M

Short % of Float

1.64%

Short % of Shares Outs.

1.62%

% Held by Insiders

0.84%

% Held by Institutions

87.23%

Beta

1.02

PEG Ratio

3.42

52w. high/low

107.92/67.13

Avg. Daily Volume

2.99M

Return %

Stock

S&P 500

1 year

(13.18)

3.92

3 years

17.74

34.34

5 years

80.16

55.95

Scale: |

High

Low

5.58

3.47

7.35

4.41

14.24

7.05

15.30

10.27

18.46

11.31

15.83

10.10

22.38

10.51

27.81

20.46

40.58

24.07

40.48

28.85

58.33

36.89

82.55

46.95

92.08

51.51

131.73

78.44

131.10

67.13

89.72

73.54

Currency: USD

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Revenue per share

1.59

1.85

1.96

2.12

2.44

2.76

3.05

3.64

3.86

4.64

5.43

5.93

6.96

7.05

8.39

8.70

8.94

Earnings per share

0.16

0.19

0.34

0.32

0.34

0.43

0.58

1.27

0.77

0.89

0.92

1.15

1.68

1.32

2.41

2.46

2.41

FCF per share

0.21

0.11

0.15

0.28

0.33

0.36

0.54

1.45

0.69

0.76

1.30

1.09

1.44

1.04

2.25

1.57

1.60

Dividends per share

- -

CAPEX per share

0.09

0.12

0.09

0.13

0.19

0.16

0.15

0.16

0.34

0.28

0.39

0.45

0.65

0.53

0.40

0.41

Book Value per sh.

1.21

1.31

1.71

1.92

1.95

2.15

2.33

3.43

3.87

4.10

4.67

5.00

6.64

7.35

9.36

9.38

9.73

Comm.Shares outs.

688

670

676

682

688

689

670

639

647

639

633

628

625

623

624

619

615

Avg. annual P/E ratio

24.9

23.1

16.3

29.3

38.2

34.6

21.1

12.1

30.9

36.5

38.9

41.3

39.6

57.0

42.3

39.3

34.8

P/E to S&P500

1.4

1.1

0.2

1.4

2.3

1.2

0.7

1.5

1.6

1.7

1.6

1.5

1.4

1.9

1.4

Avg. annual div. yield

- -

Revenue (m)

1,091

1,238

1,321

1,447

1,679

1,900

2,046

2,323

2,494

2,964

3,435

3,723

4,348

4,386

5,233

5,382

5,501

Operating margin

15.8%

16.0%

18.0%

19.6%

17.9%

21.5%

22.2%

20.8%

25.8%

26.4%

29.8%

20.1%

26.4%

20.5%

32.3%

32.5%

30.9%

Depreciation (m)

107

135

140

161

Net profit (m)

113

129

229

218

237

293

392

811

495

570

584

722

1,047

823

1,503

1,522

1,489

Income tax rate

24.6%

21.6%

24.7%

18.7%

16.5%

25.0%

24.0%

29.1%

20.5%

22.8%

43.6%

5.1%

10.3%

10.2%

11.7%

13.9%

14.0%

Net profit margin

10.4%

17.3%

15.1%

14.1%

15.4%

19.1%

34.9%

19.8%

19.2%

17.0%

19.4%

24.1%

18.8%

28.7%

28.3%

27.1%

Working capital (m)

206

433

599

695

833

945

1,380

1,860

1,572

1,708

1,129

1,410

2,082

2,197

2,148

2,073

2,175

Long-term debt (m)

176

- -

150

189

593

598

600

822

438

594

668

665

666

663

Equity (m)

835

879

1,158

1,308

1,338

1,479

1,559

2,191

2,503

2,619

2,956

3,140

4,148

4,574

5,836

5,807

5,978

ROIC

11.7%

11.8%

17.4%

15.4%

14.5%

15.8%

16.8%

26.6%

14.2%

14.7%

13.9%

16.9%

19.1%

13.2%

20.3%

21.1%

19.3%

Return on capital

11.1%

12.3%

19.0%

15.3%

14.5%

17.8%

19.3%

32.9%

15.8%

16.8%

18.6%

14.9%

18.3%

12.9%

20.2%

21.5%

19.6%

Return on equity

13.5%

14.7%

19.8%

16.7%

17.7%

19.8%

25.1%

37.0%

19.8%

21.7%

19.7%

23.0%

25.2%

18.0%

25.8%

26.2%

24.9%

Plowback ratio

100.0%

Div.&Repurch./FCF

62.4%

322.7%

28.4%

57.3%

108.9%

99.1%

124.5%

20.2%

43.5%

114.8%

78.7%

94.7%

11.4%

96.7%

36.6%

177.4%

159.4%

Capital Structure

28 Apr · 2023 | Q1

All numbers in millions

Total liabilities

$ 2,589

Total assets

$ 8,651

Long-term debt

$ 663

Cash and equiv.

$ 873

Goodwill

$ 1,308

Retained earnings

$ 7,931

Common stock

608

Enterprise Value

$ 51,755

Working Capital

Currency: USD, in millions

2020

2021

2022

Cash & Investments

1,403

1,467

1,215

Receivables

603

665

699

Inventory

802

727

876

Other

283

(108)

Current assets

3,091

3,181

3,096

Acc. Payable

197

205

202

Debt due

Other

670

802

795

Current liabilities

894

1,032

1,022

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

2.86%

9.96%

11.54%

Cash flow

(30.57)%

22.37%

28.41%

Earnings

1.25%

26.85%

24.09%

Dividends

- -

Book value

(0.50)%

17.36%

16.44%

Insider Trading

Type

Date

Mussallem Michael A

Exempt

29,350

06/01/23

Mussallem Michael A

Sale

5,300

06/01/23

Mussallem Michael A

Sale

5,396

06/01/23

Mussallem Michael A

Sale

18,654

06/01/23

Mussallem Michael A

Exempt

29,350

06/01/23

Quarterly Revenue

Currency: USD, in millions

Year

Total

2021

1,217

1,376

1,310

1,330

5,233

2022

1,341

1,374

1,319

1,348

5,382

2023

1,460

- -

Earnings per share

Currency: USD

Year

Total

2021

0.54

0.78

0.55

0.54

2.41

2022

0.60

0.66

0.55

0.64

2.46

2023

0.56

- -

Quarterly dividends paid

Currency: USD

Year

Total

2021

- -

2022

- -

2023

- -

Company Description

Sector:

Healthcare

Industry:

Medical Devices

CEO:

Mr. Bernard J. Zovighian

Full-time employees:

17,300

City:

Irvine

Address:

One Edwards Way

IPO:

Mar 27, 2000

CIK:

0001099800

Website:

edwards.com

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Powered by AI

Edwards Lifesciences Corporation

85.72